Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.97
LGND's Cash to Debt is ranked lower than
80% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. LGND: 0.97 )
Ranked among companies with meaningful Cash to Debt only.
LGND' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.63 Max: No Debt
Current: 0.97
Equity to Asset 0.57
LGND's Equity to Asset is ranked lower than
64% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. LGND: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
LGND' s Equity to Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.05 Max: 0.57
Current: 0.57
-0.49
0.57
Interest Coverage 2.32
LGND's Interest Coverage is ranked lower than
91% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LGND: 2.32 )
Ranked among companies with meaningful Interest Coverage only.
LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.07  Med: 4.04 Max: 9999.99
Current: 2.32
0.07
9999.99
F-Score: 7
Z-Score: 6.30
M-Score: -0.59
WACC vs ROIC
8.30%
176.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 38.00
LGND's Operating margin (%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. LGND: 38.00 )
Ranked among companies with meaningful Operating margin (%) only.
LGND' s Operating margin (%) Range Over the Past 10 Years
Min: -1963.29  Med: -19.93 Max: 38
Current: 38
-1963.29
38
Net-margin (%) 357.80
LGND's Net-margin (%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. LGND: 357.80 )
Ranked among companies with meaningful Net-margin (%) only.
LGND' s Net-margin (%) Range Over the Past 10 Years
Min: -798.16  Med: 8.48 Max: 2184.64
Current: 357.8
-798.16
2184.64
ROE (%) 176.94
LGND's ROE (%) is ranked higher than
99% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. LGND: 176.94 )
Ranked among companies with meaningful ROE (%) only.
LGND' s ROE (%) Range Over the Past 10 Years
Min: -1046.55  Med: 31.67 Max: 997.71
Current: 176.94
-1046.55
997.71
ROA (%) 68.37
LGND's ROA (%) is ranked higher than
99% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. LGND: 68.37 )
Ranked among companies with meaningful ROA (%) only.
LGND' s ROA (%) Range Over the Past 10 Years
Min: -56.92  Med: 3.08 Max: 112.83
Current: 68.37
-56.92
112.83
ROC (Joel Greenblatt) (%) 1660.00
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. LGND: 1660.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LGND' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1252.88  Med: -214.44 Max: 6370.4
Current: 1660
-1252.88
6370.4
Revenue Growth (3Y)(%) 28.90
LGND's Revenue Growth (3Y)(%) is ranked higher than
80% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. LGND: 28.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LGND' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -65  Med: 6.20 Max: 91
Current: 28.9
-65
91
EBITDA Growth (3Y)(%) 112.50
LGND's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. LGND: 112.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LGND' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -76.7  Med: -13.90 Max: 112.5
Current: 112.5
-76.7
112.5
» LGND's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

LGND Guru Trades in Q2 2015

Jim Simons 96,094 sh (New)
Ken Fisher 80,608 sh (-1.59%)
RS Investment Management 982,960 sh (-17.22%)
» More
Q3 2015

LGND Guru Trades in Q3 2015

RS Investment Management 1,379,230 sh (+40.31%)
Ken Fisher 70,683 sh (-12.31%)
Jim Simons 72,200 sh (-24.87%)
» More
Q4 2015

LGND Guru Trades in Q4 2015

Paul Tudor Jones 2,468 sh (New)
Jim Simons 174,300 sh (+141.41%)
Ken Fisher 70,583 sh (-0.14%)
RS Investment Management 1,089,730 sh (-20.99%)
» More
Q1 2016

LGND Guru Trades in Q1 2016

Ken Fisher 70,583 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 10.07
LGND's P/E(ttm) is ranked higher than
83% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. LGND: 10.07 )
Ranked among companies with meaningful P/E(ttm) only.
LGND' s P/E(ttm) Range Over the Past 10 Years
Min: 0.99  Med: 94.65 Max: 269.4
Current: 10.07
0.99
269.4
Forward P/E 22.62
LGND's Forward P/E is ranked lower than
66% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. LGND: 22.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.07
LGND's PE(NRI) is ranked higher than
83% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. LGND: 10.07 )
Ranked among companies with meaningful PE(NRI) only.
LGND' s PE(NRI) Range Over the Past 10 Years
Min: 7.16  Med: 117.42 Max: 99999999.99
Current: 10.07
7.16
99999999.99
Price/Owner Earnings (ttm) 50.01
LGND's Price/Owner Earnings (ttm) is ranked lower than
60% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. LGND: 50.01 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LGND' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.54  Med: 50.01 Max: 1246.25
Current: 50.01
1.54
1246.25
P/B 7.92
LGND's P/B is ranked lower than
78% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. LGND: 7.92 )
Ranked among companies with meaningful P/B only.
LGND' s P/B Range Over the Past 10 Years
Min: 5.63  Med: 21.63 Max: 174.72
Current: 7.92
5.63
174.72
P/S 35.58
LGND's P/S is ranked lower than
73% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. LGND: 35.58 )
Ranked among companies with meaningful P/S only.
LGND' s P/S Range Over the Past 10 Years
Min: 3.34  Med: 15.94 Max: 714.32
Current: 35.58
3.34
714.32
PFCF 93.70
LGND's PFCF is ranked lower than
83% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. LGND: 93.70 )
Ranked among companies with meaningful PFCF only.
LGND' s PFCF Range Over the Past 10 Years
Min: 33.59  Med: 83.55 Max: 475.54
Current: 93.7
33.59
475.54
POCF 61.39
LGND's POCF is ranked lower than
79% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. LGND: 61.39 )
Ranked among companies with meaningful POCF only.
LGND' s POCF Range Over the Past 10 Years
Min: 21.96  Med: 63.61 Max: 3131.43
Current: 61.39
21.96
3131.43
EV-to-EBIT 92.07
LGND's EV-to-EBIT is ranked lower than
86% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. LGND: 92.07 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -889.8  Med: -6.40 Max: 544.7
Current: 92.07
-889.8
544.7
EV-to-EBITDA 83.99
LGND's EV-to-EBITDA is ranked lower than
86% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. LGND: 83.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -226.2  Med: -4.85 Max: 816.4
Current: 83.99
-226.2
816.4
Shiller P/E 55.96
LGND's Shiller P/E is ranked lower than
53% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. LGND: 55.96 )
Ranked among companies with meaningful Shiller P/E only.
LGND' s Shiller P/E Range Over the Past 10 Years
Min: 39.8  Med: 97.81 Max: 2564
Current: 55.96
39.8
2564
Current Ratio 10.35
LGND's Current Ratio is ranked higher than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. LGND: 10.35 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.48 Max: 10.35
Current: 10.35
0.57
10.35
Quick Ratio 10.27
LGND's Quick Ratio is ranked higher than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. LGND: 10.27 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.37 Max: 10.27
Current: 10.27
0.53
10.27
Days Inventory 84.79
LGND's Days Inventory is ranked higher than
63% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. LGND: 84.79 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 59.78 Max: 151.94
Current: 84.79
33.18
151.94
Days Sales Outstanding 31.32
LGND's Days Sales Outstanding is ranked higher than
78% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. LGND: 31.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 53.36 Max: 1057.37
Current: 31.32
5.79
1057.37
Days Payable 256.59
LGND's Days Payable is ranked higher than
86% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. LGND: 256.59 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 251.59  Med: 307.55 Max: 822.72
Current: 256.59
251.59
822.72

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.25
LGND's Price/Tangible Book is ranked lower than
77% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. LGND: 10.25 )
Ranked among companies with meaningful Price/Tangible Book only.
LGND' s Price/Tangible Book Range Over the Past 10 Years
Min: 9.19  Med: 14.46 Max: 206.67
Current: 10.25
9.19
206.67
Price/Projected FCF 8.44
LGND's Price/Projected FCF is ranked lower than
71% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. LGND: 8.44 )
Ranked among companies with meaningful Price/Projected FCF only.
LGND' s Price/Projected FCF Range Over the Past 10 Years
Min: 7.57  Med: 7.57 Max: 7.57
Current: 8.44
Price/Median PS Value 2.24
LGND's Price/Median PS Value is ranked lower than
83% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. LGND: 2.24 )
Ranked among companies with meaningful Price/Median PS Value only.
LGND' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.85 Max: 13.46
Current: 2.24
0.32
13.46
Price/Graham Number 2.13
LGND's Price/Graham Number is ranked higher than
54% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. LGND: 2.13 )
Ranked among companies with meaningful Price/Graham Number only.
LGND' s Price/Graham Number Range Over the Past 10 Years
Min: 1.28  Med: 2.65 Max: 8.13
Current: 2.13
1.28
8.13
Earnings Yield (Greenblatt) (%) 1.10
LGND's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. LGND: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LGND' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 1.20 Max: 1.7
Current: 1.1
0.2
1.7

More Statistics

Revenue(Mil) $72
EPS $ 12.00
Beta0.95
Short Percentage of Float24.50%
52-Week Range $71.63 - 131.84
Shares Outstanding(Mil)20.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 118 156 214
EPS($) 2.41 5.34 8.48
EPS without NRI($) 2.41 5.34 8.48

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.
» More Articles for NAS:LGND

Headlines

Articles On GuruFocus.com
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Pharma Adds Tech, Grows On Partners’ Success Apr 29 2016
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming... Apr 22 2016
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming... Apr 22 2016
Spectrum Pharma Jumps on FDA Orphan Designation Apr 20 2016
VKTX: Positive Phase 1b Data Presented for VK2809 in Hypercholestermic Patients; Recent M&A Activity... Apr 15 2016
Ionis Pharmaceuticals: Valuation Compared to Its Peers Apr 14 2016
Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher? Apr 08 2016
Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic... Apr 07 2016
Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics Mar 28 2016
Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics Mar 28 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K/A, Financial Statements and Exhibits Mar 22 2016
Gilead and 4 Other Buy Stocks in the Biotech Industry Mar 22 2016
5 Big-Name Medical Stocks Show Notable Chart Action Mar 15 2016
Valeant Crashes To 4-Year Low; Eli Lilly Hits 1-Year Low Mar 15 2016
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for... Mar 15 2016
VKTX: Phase 2 Clinical Trial of VK2809 in Hypercholesterolemia to Initiate Mid-2016… Mar 11 2016
Coverage initiated on Ligand Pharma by Sidoti Mar 11 2016
LIGAND PHARMACEUTICALS INC Financials Mar 03 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K/A, Financial Statements and Exhibits Mar 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK